Tirzepatide 10 mg/vial – US Stock

Tirzepatide 10 mg/vial from Hilma Biocare is a dual GIP and GLP-1 receptor agonist supplied as lyophilized powder. Tirzepatide is a modified 39-amino-acid peptide designed to interact with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

Product Overview

Tirzepatide is an analogue of GIP with additional GLP-1 receptor activity. The molecule has been chemically modified through lipidation to support metabolic stability and its interaction with target receptors.

The supplied product information identifies tirzepatide in connection with glycemic control and weight management. Its pharmacological activity involves pathways regulating insulin secretion, glucagon, glucose metabolism, appetite, and lipid metabolism.

The product specifications state an active half-life of up to 5 days and identify the product as an injectable lyophilized powder containing 10 mg per vial.

Active Compound

The stated active compound is Tirzepatide, a dual agonist of the GIP and GLP-1 receptors.

Form and Strength

The product is supplied as lyophilized powder for injection, with 10 mg of tirzepatide per vial.

Product Characteristics

According to the supplied specifications, Tirzepatide has the following characteristics:

• Dual GIP and GLP-1 receptor agonist
• 39-amino-acid peptide
• Lipidated peptide structure
• Injectable lyophilized powder
• 10 mg per vial
• Active half-life of up to 5 days
• One vial per pack
• Aromatization listed as absent
• Water retention described as situation-dependent

Product Specifications

Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, combining the activity of two incretin pathways.

GIP Receptor Activity

Tirzepatide mimics the activity of naturally occurring GIP. GIP receptor activation is involved in glucose-dependent insulin secretion and broader metabolic regulation.

GLP-1 Receptor Activity

Tirzepatide also activates GLP-1 receptors. This pathway is associated with insulin secretion, glucagon regulation, gastric function, and appetite-related signaling.

Combined GIP and GLP-1 Activity

The dual receptor activity distinguishes tirzepatide from compounds that selectively target GLP-1 receptors. The supplied information describes effects on glucose and lipid metabolism and reports changes in adiponectin and adipokine levels during clinical treatment.

Pharmacokinetic Characteristics

The supplied product information reports that peak tirzepatide concentrations occur approximately 24–48 hours after administration, while steady-state concentrations are reached after approximately 4–5 weeks of treatment.

The source also reports a volume of distribution of 5.27 L and clearance of 0.0288 L/h. It states that pharmacokinetics are not altered by renal impairment.

These pharmacokinetic figures are reproduced as source-based product information and should not be interpreted as personalized clinical guidance.

Clinical Use and Research

The supplied information identifies tirzepatide for improving glycemic control in adults with type 2 diabetes in combination with diet and exercise and discusses its role in weight management.

Clinical effects can vary substantially between individuals. The information presented here does not establish an expected outcome for a particular customer.

Reported Side Effects

The supplied product information identifies gastrointestinal effects as common potential adverse reactions, including:

• Nausea
• Upset stomach
• Constipation
• Abdominal pain

The source also identifies potentially serious adverse events, including hypoglycemia, pancreatitis, kidney-related problems, thyroid-related concerns, and allergic reactions.

Anyone considering tirzepatide should discuss their medical history, existing conditions, and other medications with a qualified healthcare professional.

Contraindications and Precautions

According to the supplied information, tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

The source also states that tirzepatide is not indicated for people with type 1 diabetes.

Because tirzepatide affects glucose metabolism and gastrointestinal function, medical evaluation is appropriate before use, particularly for individuals taking other glucose-lowering medications.

Drug Interactions

The supplied source identifies potential interaction considerations involving insulin and other antidiabetic medications, particularly because of the potential for altered blood glucose levels. It also mentions medications affecting gastrointestinal motility and certain blood-pressure medications.

Customers should provide their healthcare professional with a complete list of prescription medicines, over-the-counter products, supplements, and other compounds before considering tirzepatide.

Important Information

Tirzepatide is a biologically active pharmaceutical peptide. The information on this page is provided for product identification and general informational purposes and does not constitute personalized medical advice.

No dosing recommendations, injection instructions, treatment schedules, dose-escalation protocols, or individualized weight-management plans are provided. The dosing information appearing in the supplied source has intentionally not been converted into usage instructions.

About Hilma Biocare USA

Tirzepatide 10 mg/vial is part of the Hilma Biocare product range. The product contains a stated 10 mg quantity of tirzepatide and is supplied as one vial of lyophilized injectable powder, listed as US Stock.